{"id":531056,"date":"2021-02-20T18:44:02","date_gmt":"2021-02-20T18:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531056"},"modified":"2021-02-20T18:44:02","modified_gmt":"2021-02-20T18:44:02","slug":"programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players_531056.html","title":{"rendered":"Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC): Overview, Epidemiology, Treatment Market, Emerging Drugs and Key players"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC): Overview, Epidemiology, Treatment Market, Emerging Drugs and Key players\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC): Overview, Epidemiology, Treatment Market, Emerging Drugs and Key players\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast &#8211; 2030\u2019 report delivers an in-depth understanding of the PD-L1 NSCLC ,historical and forecasted epidemiology as well as the PD-L1 NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\">PD-L1 (also known as CD274) is considered an immune checkpoint is facilitating anti-tumor suppression of the immune pathway.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>How has PD-L1 NSCLC impacted people&#8217;s lives?<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total cases of Programmed death-ligand 1 (PD-L1) mutated NSCLC in 7MM was&nbsp;<strong>242,014&nbsp;<\/strong>in 2017.&nbsp;<\/li>\n<li>Programmed death-ligand 1 (PD-L1) NSCLC cases in the United States in 2017 was&nbsp;<strong>89,597.<\/strong>&nbsp;<\/li>\n<li>Programmed death-ligand 1 (PD-L1) NSCLC cases in Spain in 2017 was&nbsp;<strong>11,585.&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>How will Disease transform PD-L1 NSCLC Market?&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">Pembrolizumab has received US Food and Drug Administration (FDA) approval for the frontline treatment of metastatic nonsquamous NSCLC in combination with pemetrexed and carboplatin, irrespective of programmed cell death ligand 1 (PD-L1) expression. This combination is the most preferred treatment option for those with PD-L1 expression &lt;50% or unknown advanced adenocarcinomas. However, atezolizumab with carboplatin and taxane-based regimens are also appropriate and have regulatory approval in this setting as well. The combination of platinum-based doublet chemotherapy, bevacizumab, and atezolizumab is a potential alternative in patients with nonsquamous NSCLC, and it has received FDA approval for this indication.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&#8220;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ppr\" target=\"_blank\"><strong>Programmed death-ligand 1 (PD-L1) mutated NSCLC market size<\/strong>&nbsp;<\/a>in 7MM was&nbsp;<strong>USD 6,536 million&nbsp;<\/strong>in 2017&#8243;.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Many drivers and barriers will influence the PD-L1 mutated NSCLC market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<strong>Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing Use of Biomarker Testing<\/li>\n<li>Increase in the Mutation Specific Trials Activity<\/li>\n<li>Increasing Incidence of Programmed death-ligand 1 (PD-L1) mutated NSCLC<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><strong>Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Cost-Effectiveness of Therapies<\/li>\n<li>Cost of Therapies<\/li>\n<li>Burden of Disease<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Which biotechnical companies are developing PD-L1 NSCLC drugs?&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The dynamics of the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ppr%20\" target=\"_blank\"><strong>Programmed death-ligand 1 (PD-L1) mutated NSCLC market<\/strong><\/a>&nbsp;is anticipated to change in the coming years owing to the rise in numbers of company&#8217;s taking an interest in the development of specific drugs for Programmed death-ligand 1 (PD-L1)&nbsp;<\/p>\n<p style=\"text-align: justify;\">mutated NSCLC, along with increasing awareness and knowledge towards this mutation.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Key players, such as&nbsp;<strong>Canakinumab (ACZ885): Novartis Pharmaceutical, Avelumab (Bavencio): Merck KGaA and Pfizer; Libtayo (Cemiplimab): Regeneron Pharmaceuticals; M7824 (Bintrafusp alfa): GlaxoSmithKline\/Merck KGaA&nbsp;<\/strong>and others are involved in developing drugs for Programmed death-ligand 1 (PD-L1) mutated NSCLC.<strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;Request for sample pages @&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ppr%20\" target=\"_blank\">PD-L1 NSCLC Market Landscape<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast &#8211; 2030\u2019 report delivers an in-depth understanding of the PD-L1 NSCLC ,historical and forecasted epidemiology as well as the PD-L1 NSCLC &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/programmed-deathligand-1-pdl1-nonsmall-cell-lung-cancer-nsclc-overview-epidemiology-treatment-market-emerging-drugs-and-key-players_531056.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-531056","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531056"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531056\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}